Age, years | 502 | 57±12 |
Female | 502 | 244 (47) |
BMI, kg·m−2 | 498 | 27.8±5.6 |
Duration of disease, years | 308 | 22±18 |
Duration of disease >10 years | 308 | 194 (63) |
Age at onset, years | 308 | 35±21 |
Onset during childhood ≤18 years | 321 | 93 (29) |
Late onset ≥40 years | 321 | 144 (45) |
Exacerbations in year before biologic, n | 391 | 3.08±3.1 |
Budesonide-equivalent dose, μg | 350 | 1600 (1600–1600) |
mOCS | 502 | 187 (37) |
Median dose, mg | 137 | 10 (5–15) |
Biologic | 502 | |
Mepolizumab | | 355 (71) |
Reslizumab | | 26 (5) |
Benralizumab | | 121 (24) |
Switchers | 502 | 129 (26) |
FEV1, L | 436 | 2.23±0.85 |
FEV1, % pred | 432 | 69±21 |
FEV1/FVC | 421 | 0.65±0.13 |
ACQ score | 312 | 2.48±1.29 |
Blood eosinophils, ×109 L−1 | 415 | 0.32 (0.12–0.6) |
Blood eosinophils ≥0.3×109 L−1 | 415 | 227 (55) |
IgE, IU·mL−1 | 258 | 128 (55–350) |
IgE ≥150 IU·mL−1 | 258 | 119 (46) |
FENO, ppb | 352 | 32 (17–64) |
Smoking status | 486 | |
Never-smoker | | 252 (52) |
Ex-smoker | | 225 (46) |
Current smoker | | 9 (2) |
Pack-years | 292 | 17.7±13.8 |
Allergic rhinitis | 480 | 214 (46) |
Atopic dermatitis | 476 | 63 (13) |
Chronic rhinosinusitis | 474 | 275 (58) |
Nasal polyps | 478 | 208 (44) |
Aspirin sensitivity | 475 | 39 (8) |
Bronchiectasis | 478 | 99 (21) |
Vocal cord dysfunction | 471 | 10 (2) |
ABPA | 475 | 14 (3) |
EGPA | 473 | 20 (6) |
Dysfunctional breathing | 474 | 27 (6) |
COPD | 470 | 116 (25) |
GORD | 474 | 146 (31) |
Cardiovascular disease | 475 | 149 (31) |
Diabetes | 477 | 55 (12) |
OSA | 475 | 55 (12) |